Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Authors
Category Primary study
JournalBlood
Year 2019
This article has no abstract
Epistemonikos ID: af707f5487383dea14c6cb1c5a94e484193efcc5
First added on: Feb 11, 2025